Verastem (NASDAQ:VSTM) stock is falling hard on Friday following the release of new clinical trial data for its metastatic pancreatic cancer treatment.
The company is conducting a Phase 1/2 clinical trial of avutometinib plus defactinib in combination with gemcitabine and Nab-paclitaxel. The results were positive and that initially saw VSTM stock rally higher this morning.
However, investors quickly noticed the safety data included in these results. 12 patients in the trial suffered from emergent serious adverse events. That includes 11 with grade ≥3 events. Among these were blood bilirubin increase, biliary obstruction, febrile neutropenia, pulmonary embolism, sepsis, anaemia, pneumoperitoneum, septic shock, skin infection and more.
John Hayslip, Chief Medical Officer at Verastem, said the following about the clinical trial results:
“Metastatic pancreatic cancer continues to be a challenging cancer to treat and these data support the intent behind the Therapeutic Accelerator Award that we received from PanCAN to develop new therapies faster and more efficiently than in historical studies.”
VSTM Stock Movement on Friday
VSTM stock is experiencing heavy trading on Friday alongside this data. That has more than 10 million shares traded as of this writing. This is a massive surge compared to its daily average trading volume of about 134,000 shares.
VSTM stock is down 61.7% as of Friday morning!
Investors will want to keep reading for more of the most recent stock market stories!
We have all of the hottest stock market news traders need to know about on Friday! Among that is what has shares of Sensei Biotherapeutics (NASDAQ:SNSE), Tharimmune (NASDAQ:THAR) and Netcapital (NASDAQ:NCPL) stock moving today. All of this news is available down below!
More Friday Stock Market News
- Why Is Sensei Biotherapeutics (SNSE) Stock Down 40% Today?
- Why Is Tharimmune (THAR) Stock Moving Today?
- Why Is Netcapital (NCPL) Stock Up 73% Today?
On Penny Stocks and Low-Volume Stocks: With only the rarest exceptions, InvestorPlace does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. That’s because these “penny stocks” are frequently the playground for scam artists and market manipulators. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand that InvestorPlace.com’s writers disclose this fact and warn readers of the risks.
Read More: Penny Stocks — How to Profit Without Getting Scammed
On the date of publication, William White did not hold (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com Publishing Guidelines.
